Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13810372 | 0.91 | CNR1 (0.49) | MGLLCNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4339388 | 0.90 | MGLL (0.62) | MGLLNPC1RAB9ASMN1; SMN2RECQL | |
| SCHEMBL4341213 | 0.89 | MEN1 (0.60) | MGLLNPC1RAB9ASMN1; SMN2RECQL | |
| SCHEMBL4328095 | 0.88 | MGLL (0.51) | MGLLNPC1RAB9ASMN1; SMN2RECQL | |
| SCHEMBL4341927 | 0.88 | MEN1 (0.53) | MGLLNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4334130 | 0.86 | LMNA (0.56) | MGLLCNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4338993 | 0.86 | MGLL (0.45) | MGLLCNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4348243 | 0.86 | PPARG (0.51) | MGLLCNR1L3MBTL1 | |
| SCHEMBL4327937 | 0.85 | MAPT (0.47) | MGLLNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4336281 | 0.85 | FPR2 (0.51) | MGLLCNR1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | MGLL 3539/4885CNR1 75/4885NPC1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.